CN Patent

CN120272480A — 用于治疗与pcsk9相关疾病的靶向寡核苷酸

Assigned to Beijing Anlong Biomedical Co ltd · Expires 2025-07-08 · 1y expired

What this patent protects

本公开涉及用于治疗与PCSK9相关疾病的靶向寡核苷酸，所述靶向寡核苷酸包含反义链，所述反义链具有如SEQ ID NO:53‑106中任一所示的序列或其片段、或所述序列或其片段的修饰序列。所述靶向寡核苷酸显著抑制中PCSK9基因表达水平，降低血液中低密度脂蛋白胆固醇(LDL‑C)水平，表现出良好的降脂效果。

USPTO Abstract

本公开涉及用于治疗与PCSK9相关疾病的靶向寡核苷酸，所述靶向寡核苷酸包含反义链，所述反义链具有如SEQ ID NO:53‑106中任一所示的序列或其片段、或所述序列或其片段的修饰序列。所述靶向寡核苷酸显著抑制中PCSK9基因表达水平，降低血液中低密度脂蛋白胆固醇(LDL‑C)水平，表现出良好的降脂效果。

Drugs covered by this patent

Patent Metadata

Patent number
CN120272480A
Jurisdiction
CN
Classification
—
Expires
2025-07-08
Drug substance claim
No
Drug product claim
No
Assignee
Beijing Anlong Biomedical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.